The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomolecular, biochemical, and radiologic evaluation and safety of chemotherapy with bevacizumab in treatment of patients affected by mCRC.
L. Rossi
No relevant relationships to disclose
E. Veltri
No relevant relationships to disclose
M. Colonna
No relevant relationships to disclose
F. Zoratto
No relevant relationships to disclose
S. Vari
No relevant relationships to disclose
M. Mottolese
No relevant relationships to disclose
M. Di Seri
No relevant relationships to disclose
A. Romiti
No relevant relationships to disclose
F. Longo
No relevant relationships to disclose
D. Giannarelli
No relevant relationships to disclose
S. Tomao
No relevant relationships to disclose